Zhengye Biotechnology Holding (ZYBT) Cash & Current Investments (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Cash & Current Investments for 3 consecutive years, with $7.3 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Current Investments rose 162.27% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 162.27% YoY) and the FY2025 annual result came in at $7.3 million, up 155.78% from the prior year.
• Cash & Current Investments rose to $7.3 million in Q4 2025 per ZYBT's latest filing, from $6.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for ZYBT reached as high as $7.3 million in Q4 2025 and fell as low as $2.8 million in Q4 2024.
• A 3-year average of $5.5 million and a median of $6.0 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments plunged 48.89% — and 2025, when it soared 162.27%.
• Year by year, Cash & Current Investments stood at $5.5 million in 2023, then tumbled by 48.89% to $2.8 million in 2024, then surged by 162.27% to $7.3 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $7.3 million, $6.6 million, and $2.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.